Slansky made it pretty clear in his recent interview that Oncosec is being primed for a buyout in the future.
Punit has spoken about going the licensing route; OncoSec does have a patent on its delivery technology. I don't know if he still thinks this way but, either way OncoSec goes, it should be good for the shareholders.